Uterine Cervical Neoplasms

Each year in the US, an estimated 200 000 patients1 receive a diagnosis of precancerous cervical lesions caused by human papillomavirus (HPV), the most common of which are cervical intraepithelial neoplasia (CIN) grades 2 (CIN2) and 3 (CIN3), also known as high-grade squamous intraepithelial lesion. Most patients undergo treatment with an excisional procedure (loop excision, cold knife cone biopsy), and some undergo an ablative procedure (cryotherapy, laser, thermal ablation). Because treatments have a 5% to 10% risk of failure (defined as residual high-grade squamous intraepithelial lesion) and about 0.5% of patients receive a diagnosis of cancer during the immediate posttreatment period (2.5 years after treatment), close monitoring after treatment is a critical step in further decreasing cervical cancer morbidity and mortality; such monitoring commonly falls within the purview of primary care clinicians. Unfortunately, only half of patients undergo the posttreatment monitoring recommended by guidelines.

This Clinical Insights article is designed to provide primary care clinicians with a comprehensive overview of monitoring patients after treatment of precancerous cervical lesions, much of which may take place outside of the obstetrics and gynecology setting. We focus on posttreatment monitoring of CIN2 and CIN3, not precancerous lesions of endocervical cells (adenocarcinoma in situ). Our article summarizes guidance provided to frontline clinicians by the American Society for Colposcopy and Cervical Pathology through a comprehensive publication, a free online calculator, and a fee-based application.

Author/s:

George F Sawaya, Bennett Lareau, Robyn Lamar

Vulvar cancer

Megan George — Fri, 27 Feb 2026 02:24:14 +0000

Date Added:

February 26, 2026

Journal/Publication:

Canadian Medical Association Journal

Publication Date:

February 23, 2026

URL:

Vulvar cancer

Type:

Meta-analyses, Reviews, and Guidelines

Format:

Article

DOI (1):

10.1503/cmaj.250797

Keywords

Vulvar cancer

Human Papillomavirus Viruses

human papillomavirus

Uterine Cervical Neoplasms

PMID (1):

41730538

MeSH

Vulvar cancer

Human Papillomavirus Viruses

Cervix Uteri

Papillomavirus Infections

uterine cervical neoplasms

Lichen Sclerosus et Atrophicus

A concise list of important things to know about vulvar cancer. James W. Mold, MD, MPH

View

Vulvar cancer is an underrecognized gynecologic malignant disease. The incidence of vulvar cancer is 2.3 per 100 000 people in Canada, and is increasing with the rising prevalence of human papillomavirus (HPV). More than 90% of vulvar cancers are squamous cell carcinomas (SCC), mostly diagnosed after age 65 years. Vulvar SCC mimics nonspecific inflammation, which often delays diagnosis. Risk factors include advanced age, HPV infection, lichen sclerosis, smoking, immunodeficiency, and pelvic radiation

Author/s:

Jennifer Davis, Jacob McGee, Anjali Kulkarni

Human Papillomavirus and Cancer

Megan George — Thu, 21 Aug 2025 16:13:34 +0000

Date Added:

August 21, 2025

Journal/Publication:

The New England Journal of Medicine

Publication Date:

July 30, 2025

Issue:

Volume:

393

URL:

Human Papillomavirus and Cancer

Type:

Meta-analyses, Reviews, and Guidelines

Format:

Video

DOI (1):

10.1056/NEJMp2414535

Keywords

Human Papillomavirus Viruses

Uterine Cervical Neoplasms

Papillomavirus Infections

Papillomavirus Vaccines

MeSH

Papillomavirus Vaccines

Papillomavirus Infections

uterine cervical neoplasms

Human Papillomavirus Viruses

This is a 13 ½ minute audio-review of the link between HPV and various cancers and current recommendations regarding HPV immunization. James W. Mold, MD, MPH

Free full text

View

In this Double Take video from the New England Journal of Medicine, Dr. Julie Barzilay discusses the connection between certain strains of human papillomavirus (HPV) and cancer, as well as the evidence to support the safety and efficacy of the HPV vaccine in reducing the risk of cervical neoplasia. Strategies for discussing the HPV vaccine with patients and families are also reviewed.

Author/s:

Julie R. Barzilay, Sarah Feldman, Alison E. Burke, Emily Ling, Scott Williams, Caren G. Solomon